In a first, a patient has engaged in a Phase II analysis testing of a stem cell therapy for the possible early treatment and resulting complications of their traumatic injury at the University of Texas Health Science Center in Houston.
Stem cells are a special kind of cell gaining interest and controversy in scientific usage. There are two primary stem cell types: embryonic stem cells and adult stem cells. Stem cells may one day be used to generate cells and tissues for the therapy of a variety of diseases including Parkinson's disease, Alzheimer's disease and spinal cord injury.
Trauma is the seventh leading cause of death in the USA, according to the CDC. It is the primary cause of mortality for people under the age of 45.
There is evidence that the hyperinflammatory reaction to traumatic injuries is similar to other causes of acute tissue injury. Activating and mobilizing the peripheral immune system after an injury tends to damage nearby secondary tissue.
“The use of this treatment strategy leverages a long legacy of investigation into the common mechanism of action of down-regulation of the inflammatory response to injury and how it mitigates complications of trauma,” said Dr. Charles S. Cox, a faculty member at MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences.
The clinical trial assesses the effectiveness and feasibility of "MultiStem," the therapy, in the treatment of hospitalized patients with serious hemorrhage. It will recruit up to 156 persons in the single-center study.
MultiStem cells can contribute to decrease in inflammatory cascades after serious acute injury. The research is investigating whether MultiStem modulates immune reactions to traumatic injury to alleviate secondary tissue injury.